ストックスクリーナーアプリを入手
14.77
20.63%
-3.84
アフターアワーズ：
14.89
0.12
+0.81%
前日終値:
$18.61
開ける：
$17.75
24時間の取引高:
2.55M
Relative Volume:
3.73
時価総額：
$1.90B
収益：
$628.25M
当期純損益:
$-78.55M
株価収益率:
-23.82
EPS:
-0.62
ネットキャッシュフロー:
$-29.73M
1週間 パフォーマンス:
-13.02%
1か月 パフォーマンス:
-19.86%
6か月 パフォーマンス:
+9.25%
1年 パフォーマンス:
-7.51%
1日の値動き範囲:
$14.51
$17.75
1週間の範囲:
$14.51
$19.11
52週間の値動き範囲:
$12.77
$19.11
Neogenomics Inc Stock (NEO) Company Profile
NEO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
14.77 | 1.90B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
542.31 | 207.43B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
235.07 | 169.79B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
137.47 | 39.26B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
203.27 | 36.89B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
418.05 | 34.23B | 3.84B | 866.24M | 792.60M | 10.37 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 開始されました | Jefferies | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-08-21 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-02-24 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-02-01 | アップグレード | Needham | Hold → Buy |
| 2022-08-26 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-22 | ダウングレード | Needham | Buy → Hold |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-03-29 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-29 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 再開されました | Stephens | Overweight |
| 2021-12-16 | 開始されました | Cowen | Outperform |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-02-25 | 再開されました | Needham | Buy |
| 2021-02-25 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-12-11 | 再開されました | BTIG Research | Buy |
| 2020-10-28 | 繰り返されました | Needham | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-28 | 開始されました | Guggenheim | Buy |
| 2020-07-29 | 繰り返されました | Needham | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Buy |
| 2020-04-21 | 再開されました | Stephens | Overweight |
| 2020-03-02 | 再開されました | Craig Hallum | Buy |
| 2020-02-28 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 繰り返されました | Needham | Buy |
| 2019-05-01 | 繰り返されました | Needham | Buy |
| 2019-03-29 | 繰り返されました | Needham | Buy |
| 2019-01-03 | 開始されました | Needham | Buy |
| 2018-10-24 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 開始されました | Leerink Partners | Outperform |
| 2018-05-02 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2017-08-24 | 開始されました | Gabelli & Co | Buy |
| 2016-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Neogenomics Inc (NEO) 最新ニュース
NeoGenomics Shares Fall on CEO's Plan to Retire - MarketWatch
NeoGenomics' (NEO) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
NeoGenomics (NEO) Shares Cross Below 200 DMA - Nasdaq
NeoGenomics Shares Are Falling Today: What's Going On? - Benzinga
NeoGenomics (NASDAQ:NEO) Shares Gap DownTime to Sell? - MarketBeat
NeoGenomics CEO steps down, shares fall 17% By Investing.com - Investing.com Canada
NeoGenomics (NASDAQ:NEO) Releases FY 2024 Earnings Guidance - MarketBeat
NeoGenomics, Inc. Reaffirms Earnings Guidance for Full Year Ended December 31, 2024 - Marketscreener.com
NeoGenomics Appoints Tony Zook As CEO - citybiz
NeoGenomics CEO Chris Smith to Retire; Tony Zook to Take Helm - MarketWatch
NeoGenomics Announces CEO Transition and Leadership Change - TipRanks
NeoGenomics Announces Chief Executive Officer Succession - The Bakersfield Californian
Neogenomics, Announces Retirement of Chris Smith as Board Member, Effective April 1, 2025 - Marketscreener.com
Leerink Partnrs Weighs in on NeoGenomics FY2024 Earnings - MarketBeat
NeoGenomics (NASDAQ:NEO) Sets New 12-Month HighShould You Buy? - MarketBeat
NeoGenomics stock hits 52-week high at $19.01 amid growth By Investing.com - Investing.com South Africa
NeoGenomics stock hits 52-week high at $19.01 amid growth - Investing.com
NeoGenomics CEO to Present Strategic Vision at J.P. Morgan Healthcare Conference - StockTitan
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Bakersfield Californian
NeoGenomics (NEO) Upgraded to Buy: Here's Why - MSN
The past three years for NeoGenomics (NASDAQ:NEO) investors has not been profitable - Simply Wall St
IBD Rating Upgrades: NeoGenomics Flashes Improved Price Strength - MSN
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Geode Capital Management LLC - MarketBeat
Franklin Resources Inc. Has $28.23 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Shares Bought by State Street Corp - MarketBeat
Natera expands lawsuit against NeoGenomics over RaDaR test By Investing.com - Investing.com Canada
Natera expands lawsuit against NeoGenomics over RaDaR test - Investing.com India
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics - Business Wire
Bank of America Raises NeoGenomics (NASDAQ:NEO) Price Target to $19.00 - Defense World
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma - BioSpace
BNP Paribas Financial Markets Boosts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
NeoGenomics' Breakthrough Study Shows Promise in Early Melanoma Detection Using RaDaR® Technology - StockTitan
Evaluating NeoGenomics: Insights From 4 Financial Analysts - Benzinga
NeoGenomics Getting Closer To Key Technical Measure - MSN
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting - Business Wire
Charles Schwab Investment Management Inc. Acquires 57,677 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
NeoGenomics Inc (NEO) Trading 4.33% Higher on Dec 6 - GuruFocus.com
ConcertAI and NeoGenomics announce AI software-as-a-service solution for hematology clinical research - The Cancer Letter
Edgestream Partners L.P. Sells 94,791 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research - Business Wire
ConcertAI, NeoGenomics Launch Groundbreaking 370,000-Patient Hematology Research Platform - StockTitan
NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by Bellevue Group AG - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Mutual of America Capital Management LLC Sells 1,716 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
Algert Global LLC Has $1.18 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
Natixis Advisors LLC Buys 11,936 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
Loomis Sayles & Co. L P Purchases Shares of 1,207,290 NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
(NEO) Investment Analysis - Stock Traders Daily
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable - Simply Wall St
NeoGenomics, Inc. (NASDAQ:NEO) Stock Holdings Raised by Jennison Associates LLC - MarketBeat
Neogenomics Inc (NEO) 財務データ
収益
当期純利益
現金流量
EPS
0.99%
1.64%
大文字化:
|
ボリューム (24 時間):